Overview

• In the 26-week ADJUST-T1D trial, 36% of adults with type 1 diabetes receiving semaglutide met a composite endpoint of ≥70% time in glucose range, <4% time below 70 mg/dL and ≥5% body weight loss, compared with none in the placebo group (P < .001).
• Participants on semaglutide lost an average of 8.8 kg and achieved a 0.3% greater reduction in HbA1c than those on placebo, with nearly 9% more time spent in target glucose range.
• Semaglutide was generally well tolerated, maintaining low hypoglycemia rates but causing gastrointestinal events in 53% of users versus 25% with placebo and prompting only two discontinuations.
• Although approved for type 2 diabetes and obesity, semaglutide’s use in type 1 diabetes remains investigational pending further safety and efficacy data.
• Analysis of nearly 1.7 million medical records shows semaglutide users with type 2 diabetes had significantly lower Alzheimer’s-related dementia incidence than patients on other antidiabetic therapies.